Canada’s Valeant Pharmaceuticals International Inc (VRX.TO: Quote) (VRX.N: Quote), which has offered to buy Bausch & Lomb Holdings for $8.7 billion, said it may slash 10 to 15 percent of the combined company’s workforce.
Valeant, which expects to get regulatory nod by early August, said severance plans for the United States and Canada have been finalized.
The company also said it is plans to consolidate some locations.
via Valeant Pharma says may cut 10-15 percent jobs after Bausch & Lomb deal | Business | Reuters.
Pingback: Merck / To cut 8,500 jobs | Job Market Monitor - October 1, 2013
Pingback: Teva / The drug company to cut 5,000 jobs | Job Market Monitor - October 10, 2013
Pingback: Layoffs in Pharmaceutical Industry / Due to Productivity Crisis in R&D ? | Job Market Monitor - October 11, 2013
Pingback: Novartis / To Cut 500 Jobs | Job Market Monitor - November 7, 2013
Pingback: Pharmaceutical / The Skills Gap | Job Market Monitor - November 20, 2013
Pingback: Forest Labs / To cut jobs to save $110 million | Job Market Monitor - December 2, 2013